Ascidian Therapeutics’ Post

Join us for a webinar on, "The Role of Pharmacogenomics in Patient Care," with Prof (Dr). Subhrojyoti Bhowmick, MD . Learn how genetic insights are transforming treatments, minimizing adverse reactions, and enhancing patient outcomes through personalized medicine. Register here: https://lnkd.in/dwtEZsJY #Pharmacogenomics #PersonalizedMedicine #HealthcareInnovation #PatientCare #PrecisionMedicine #MedicalWebinar

The use of #machinelearning-based techniques in #drugdiscovery requires large amounts of biomedical information. Fortunately, we have been collecting and collating vast amounts of #biospecimen-associated clinical data for over 30 years. This assures that you have comprehensive data that you can incorporate into your data-driven research workflows. Our database of images and associated clinical records can assist in revealing patterns and relationships relevant to both disease etiology and pathology, and feature: - Board-certified confirmed diagnoses, ensuring digital images are representative of disease states - Aperio full-slide images that integrate into #AI-based image analyses - Over 200 data points, some including patient outcomes - Standardized collection protocols Learn more about our solutions for #artificialintelligence development programs: https://lnkd.in/eSxNvRW7

Transforming Healthcare with Genomic Medicine🧬 Genomic medicine is at the forefront of personalized healthcare, utilizing an individual's genetic information to enhance diagnosis, predict outcomes, and tailor treatments. This approach marks a significant advancement in how we approach patient care, offering a more precise and individualized treatment strategy. Discover how precision medicine can transform your clinical practice and improve patient outcomes. 🌟 hashtag#GenomicMedicine hashtag#PersonalizedHealthcare hashtag#PrecisionMedicine hashtag#MedicalInnovation hashtag#HealthcareRevolution

Just 3 Days to Go! Don't miss our webinar on 'The Role of Pharmacogenomics in Optimizing Patient Care' with Prof (Dr). Subhrojyoti Bhowmick, MD. Explore how genetics is driving personalized treatments and improving patient safety and outcomes. Register now: https://lnkd.in/dwtEZsJY #Pharmacogenomics #PersonalizedMedicine #HealthcareInnovation #PatientCare #PrecisionMedicine #Webinar

The use of #machinelearning-based techniques in #drugdiscovery requires large amounts of biomedical information. Fortunately, we have been collecting and collating vast amounts of #biospecimen-associated clinical data for over 30 years. This assures that you have comprehensive data that you can incorporate into your data-driven research workflows. Our database of images and associated clinical records can assist in revealing patterns and relationships relevant to both disease etiology and pathology, and feature: - Board-certified confirmed diagnoses, ensuring digital images are representative of disease states - Aperio full-slide images that integrate into #AI-based image analyses - Over 200 data points, some including patient outcomes - Standardized collection protocols Learn more about our solutions for #artificialintelligence development programs: https://lnkd.in/epnT8SFW

In this video, Director of Clinical Research Chris Amidei APN, PhD, IAAN explains what clinical trials are, how they are managed ethically, and where #braintumor patients can get more information on their #clinicaltrial options. https://lnkd.in/gCewzY9Y

The integration of digital pathology with other data types enables a holistic view of disease, facilitating the development of targeted therapies. #DigitalPathology #TargetedTherapies #DataIntegration

Discover why digital marketing is crucial for Pathology Labs and Diagnostic Centers. 🌐📈  Read more: https://bit.ly/4cO2l9W #DigitalMarketing #PathologyLabs #DiagnosticCenters #HealthcareMarketing #GMBOptimization #SocialMediaMarketing #MedicalMarketing #OnlinePresence

Current manual methods for HER2 assessment are fraught with challenges. Significant challenges are the inter- and intra-reader variability and the high proportion of inconclusive cases requiring additional testing for a definitive diagnosis. These inconclusive cases pose a considerable challenge, adding costs for reflex testing, and slowing down the diagnostic process, thereby creating uncertainty for patients and clinicians alike. In this context, AI-driven precision pathology has emerged as a promising solution 💡 Read our whitepaper to learn more about Visiopharm’s IVDR-cleared solution for HER2 assessment: https://hubs.ly/Q02ljrBn0

Two new Letters to the Editor! Follow the discussion regarding the recent publication about mixed connective tissue disease. Is MCTD a distinct entity? 🔸Original Article: This study shows that MCTD is a distinct entity that can be classified using either Kasukawa or Sharp criteria and that only 25.8 per cent of patients progress to a dCTD during follow-up. 🔸Letter to the Editor: If their clinical presentation is similar and the only difference is the antibody subtype, should we not lump these disorders within the same nosological entity with a common name — that is, SSc? The cohort from Chevalier et al. offers a unique opportunity to explore this question and enrich the debate on the existence of MCTD as a distinct entity. 🔸Authors Reply: We strongly disagree with the proposal to lump MCTD and SSc under the same name. Such a decision would be a simplistic mistake, whereas striving to enhance both the SSc and MCTD classifications could be a common objective. 🔗Original Article: https://lnkd.in/djRPsKcV 🔗🔗Letter to the Editor: https://lnkd.in/dKBdX7Hi 🔗🔗🔗Authors reply: https://lnkd.in/d_hWjz2S #Sjogrens #systemic #sclerose